newsfilter
← Latest News
Business Wire·

AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023

Positive final posoleucel Phase 2 clinical data presented at ASH 2022 underscore potential as multi-virus prevention therapy and support ongoing global Phase 3 registration trial Completion of enrollment of all three